140 related articles for article (PubMed ID: 8822109)
1. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours.
Lee CS; Pirdas A
Pathol Res Pract; 1995 Nov; 191(11):1087-91. PubMed ID: 8822109
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor alpha immunoreactivity in human gallbladder and extrahepatic biliary tract tumours.
Lee CS
Eur J Surg Oncol; 1998 Feb; 24(1):38-42. PubMed ID: 9542514
[TBL] [Abstract][Full Text] [Related]
3. nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
Lee CS; Pirdas-Zivcic A
Pathology; 1994 Oct; 26(4):448-52. PubMed ID: 7892048
[TBL] [Abstract][Full Text] [Related]
4. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
5. p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
Lee CS; Pirdas A
Pathology; 1995 Apr; 27(2):117-20. PubMed ID: 7567135
[TBL] [Abstract][Full Text] [Related]
6. Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma.
Lee CS
Eur J Surg Oncol; 1997 Jun; 23(3):233-7. PubMed ID: 9236898
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.
Teh M; Wee A; Raju GC
Cancer; 1994 Sep; 74(5):1542-5. PubMed ID: 7520348
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
Shafizadeh N; Grenert JP; Sahai V; Kakar S
Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
[TBL] [Abstract][Full Text] [Related]
9. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract.
Lee CS
Cancer; 1996 Nov; 78(9):1881-7. PubMed ID: 8909306
[TBL] [Abstract][Full Text] [Related]
10. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.
Goodman MT; Yamamoto J
Cancer Causes Control; 2007 May; 18(4):415-22. PubMed ID: 17264972
[TBL] [Abstract][Full Text] [Related]
11. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions.
Tretiakova M; Antic T; Westerhoff M; Mueller J; Himmelfarb EA; Wang HL; Xiao SY
Am J Surg Pathol; 2012 Jan; 36(1):101-8. PubMed ID: 21989348
[TBL] [Abstract][Full Text] [Related]
13. Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts.
Kuo KK; Sato N; Mizumoto K; Maehara N; Yonemasu H; Ker CG; Sheen PC; Tanaka M
Hepatology; 2000 Jan; 31(1):59-64. PubMed ID: 10613729
[TBL] [Abstract][Full Text] [Related]
14. Differences in c-fos gene product expression in cancers of the gall-bladder and biliary tract.
Lee CS
Pathol Int; 1996 Oct; 46(10):771-6. PubMed ID: 8916147
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
[TBL] [Abstract][Full Text] [Related]
16. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study.
Henson DE; Schwartz AM; Nsouli H; Albores-Saavedra J
Arch Pathol Lab Med; 2009 Jan; 133(1):67-71. PubMed ID: 19123739
[TBL] [Abstract][Full Text] [Related]
17. Surgical treatment for non-dilated biliary tract with pancreaticobiliary maljunction should include excision of the extrahepatic bile duct.
Hara H; Morita S; Ishibashi T; Sako S; Dohi T; Iwamoto M; Tanigawa N
Hepatogastroenterology; 2001; 48(40):984-7. PubMed ID: 11490854
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-pyridoxylideneglutamate: a new hepatobiliary radiopharmaceutical. II. Clinical aspects.
Ronai PM; Baker RJ; Bellen JC; Collins PJ; Anderson PJ; Lander H
J Nucl Med; 1975 Aug; 16(8):728-37. PubMed ID: 1177049
[TBL] [Abstract][Full Text] [Related]
19. Risk factor for extrahepatic bile duct cancer in patients with anomalous pancreaticobiliary ductal union.
Jung YS; Lee KJ; Kim H; Kim WH; Kim IG; Yoo BM; Kim JH; Kim MW
Hepatogastroenterology; 2004; 51(58):946-9. PubMed ID: 15239220
[TBL] [Abstract][Full Text] [Related]
20. Biliary carcinoma risk in patients with pancreaticobiliary maljunction and the degree of extrahepatic bile duct dilatation.
Kamisawa T; Tu Y; Kuwata G; Egawa N; Nakajima H; Tsuruta K; Okamoto A; Matsukawa M
Hepatogastroenterology; 2006; 53(72):816-8. PubMed ID: 17153430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
